Back to Menu
Esophageal Cancer Treatment Modalities
1.Endoscopic minimally invasive treatment
For early-stage disease (Tis–T1a), endoscopic resection can be performed, with minimal trauma and rapid recovery while preserving esophageal function.
2.Surgical treatment
Resection of the tumor with partial gastrectomy, reconstruction of the alimentary tract, and achievement of negative margins with adequate lymph node dissection.
3.Neoadjuvant therapy
Preoperative chemotherapy or chemoradiotherapy is used to reduce tumor burden, increase resectability, and improve pathological complete response rates.
4.Adjuvant therapy
Postoperative chemotherapy or radiotherapy is administered based on pathological findings to eradicate microscopic residual disease and reduce recurrence risk.
5.Definitive chemoradiotherapy
For patients who are not surgical candidates, concurrent chemoradiotherapy is administered, and some patients may achieve long-term survival.
6.Palliative radiotherapy
Used to relieve dysphagia, pain, bleeding, and other symptoms in advanced disease, improving quality of life.
7.Systemic chemotherapy
A backbone therapy for advanced disease, commonly using fluoropyrimidines, platinum agents, and taxanes to prolong survival.
8.Targeted therapy
For tumors positive for HER2 or Claudin18.2, targeted agents combined with chemotherapy can improve efficacy.
9.Esophageal stent placement
A covered stent is placed endoscopically to rapidly relieve dysphagia and maintain esophageal patency.
Conclusion
Jinshazhou Hospital of Guangzhou University of Chinese Medicine emphasizes that esophageal cancer is a gastrointestinal malignancy that seriously threatens health. Progressive dysphagia can lead to malnutrition, and advanced disease is prone to metastasis, resulting in an overall poor prognosis. Early symptoms are often subtle, and many patients are diagnosed at intermediate to advanced stages. Early diagnosis and standardized treatment are pivotal for improving outcomes. High-risk populations should undergo regular screening, and individualized plans should be developed through MDT-based multidisciplinary collaboration.
Esophageal Cancer Treatment Modalities
1.Endoscopic minimally invasive treatment
For early-stage disease (Tis–T1a), endoscopic resection can be performed, with minimal trauma and rapid recovery while preserving esophageal function.
2.Surgical treatment
Resection of the tumor with partial gastrectomy, reconstruction of the alimentary tract, and achievement of negative margins with adequate lymph node dissection.
3.Neoadjuvant therapy
Preoperative chemotherapy or chemoradiotherapy is used to reduce tumor burden, increase resectability, and improve pathological complete response rates.
4.Adjuvant therapy
Postoperative chemotherapy or radiotherapy is administered based on pathological findings to eradicate microscopic residual disease and reduce recurrence risk.
5.Definitive chemoradiotherapy
For patients who are not surgical candidates, concurrent chemoradiotherapy is administered, and some patients may achieve long-term survival.
6.Palliative radiotherapy
Used to relieve dysphagia, pain, bleeding, and other symptoms in advanced disease, improving quality of life.
7.Systemic chemotherapy
A backbone therapy for advanced disease, commonly using fluoropyrimidines, platinum agents, and taxanes to prolong survival.
8.Targeted therapy
For tumors positive for HER2 or Claudin18.2, targeted agents combined with chemotherapy can improve efficacy.
9.Esophageal stent placement
A covered stent is placed endoscopically to rapidly relieve dysphagia and maintain esophageal patency.
Conclusion
Jinshazhou Hospital of Guangzhou University of Chinese Medicine emphasizes that esophageal cancer is a gastrointestinal malignancy that seriously threatens health. Progressive dysphagia can lead to malnutrition, and advanced disease is prone to metastasis, resulting in an overall poor prognosis. Early symptoms are often subtle, and many patients are diagnosed at intermediate to advanced stages. Early diagnosis and standardized treatment are pivotal for improving outcomes. High-risk populations should undergo regular screening, and individualized plans should be developed through MDT-based multidisciplinary collaboration.